The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Clinical trial NCT03805789 · COMPLETED
Trial details
- NCT number
- NCT03805789
- Sponsor
- CSL Behring
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-27
- Primary completion
- 2026-03-19
- Enrollment
- 222
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.